BergenBio Fundamentale Forhold (BGBIO)

[Savepig]

Trinity Delta (trinity_delta)

[larsmkn]

Sykt BULL! Kursmålet hevet med hele 3%!

Så lenge det går oppover så skal man vel være fornøyd.

Litt lol å se den personen eller roboten som tidevis er inne for å kjøpe 1 aksje for å kjøre kursen oppover

[TekBot]

29/11-2018 12:21:46: (BGBIO) BerGenBio to Present at the 3rd Nordic-American Life Science Conference in New York City November 29, 2018

Bergen, Norway, November 29th, 2018 - BerGenBio ASA (OSE:BGBIO), announces that
Richard Godfrey, CEO of BerGenBio, is scheduled to present an overview of the
Company’s business and ongoing phase II clinical development programme with its
…

Vis børsmeldingen

first-in-class selective AXL inhibitor bemcentinib at Nordic American Life
Science Conference in New York City on November 29th 2018 at 10:30 AM (EST).

Presentation will be available at www.bergenbio.com in the section: Investors/
Presentations following the presentation.

• END -

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
advanced and aggressive cancers. The company’s proprietary lead candidate,
bemcentinib, is a potential first-in- class, selective AXL inhibitor in a broad
phase II clinical development programme. Ongoing clinical trials are
investigating bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including immunotherapies,
targeted therapies and chemotherapy), and as a single agent.

In parallel, BerGenBio is developing a companion diagnostics test to identify
patient populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials and support a precision
medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

Contacts

Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
[email protected]
+47 995 13 891

International Media Relations

David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
[email protected]
+44 207 638 9571

Forward-Looking Statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20181129.OBI.20181129S37

[Realize_1]

Noen som ser noe nytt her?
#Larsmkn

BGB_DnB-Nordic-American-Nov-18.pdf

[Flottesen]

Ikke noe nytt som jeg kan se. Det er en investorkonferanse, så det er vel heller ikke så mye nytt å forvente av kliniske data. Mer spent på hva som kommer nå på ASH.

[pdx]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @larsmkn (164 likes)

Ok, så da har jeg fått kikket litt.

2. @Flottesen (30 likes)

Ja, fin omtale.

3. @Morgo26 (18 likes)

And there is your late breaking abstract announcement

Resten av topp 10:

4. @Fornybar (16 likes)

5. @Boykie (13 likes)

6. @sanoda (10 likes)

7. @Savepig (10 likes)

8. @Ida (8 likes)

9. @Krieghoff (8 likes)

10. @drdr (7 likes)

Gratulerer!

[Troso]

Noe nytt her?
https://ash.confex.com/ash/2018/webprogram/Paper120380.html

[Flottesen]

De skal presentere i natt, vi får nok resultatene i morgen tidlig.

[TekBot]

03/12-2018 03:15:12: (BGBIO) BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH

· 43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker
positive R/R AML/MDS patients (6 out of 14)
· Phase II trial continues in combination with chemotherapeutics in first line
…

Vis børsmeldingen

AML
· Bemcentinib with decitabine cohort has completed recruitment, data will be
submitted for presentation at upcoming medical congress
Bergen, Norway, 3 Dec 2018 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company focused on developing a pipeline of first-in-class AXL
kinase inhibitors to treat multiple cancer indications, today announced that it
presented a comprehensive analysis of monotherapy data from its BGBC003 clinical
trial (NCT02488408) with selective AXL inhibitor bemcentinib in patients with
relapsed/refractory Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic
Syndrome (MDS).

In a poster presentation at the 60th American Society of Hematology Annual
Meeting (ASH) in San Diego entitled: “Comprehensive Analysis of the Dose
Escalation, Expansion and Correlates in the Ph I/II Trial BGBC003 with the
Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and
MDS”, Professor Sonja Loges, attending physician at the University Hospital in
Hamburg-Eppendorf and lead investigator of the BGBC003 trial, detailed the
following:

· 14 of 26 (54%) of patients found to be AXL positive (denoted by low serum
AXL, sAXL, levels at start of treatment)
· Response rate of 43% CR/Cri/CRp to bemcentinib monotherapy in AXL positive
patients and 22% overall.
· Mild and manageable side effect profile with a low incidence of Grade 3/4
events and low incidence of haematological toxicity.

Furthermore, the Company announces that enrolment is complete into the phase II
combination cohort of bemcentinib and decitabine in first line AML. Analysis of
the activity of the combination will be submitted for presentation at a future
medical congress.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “I am very
encouraged by the data presented today, we are consistently seeing AXL positive
patients report a superior response to bemcentinib therapy alone or in
combination with standard of care therapy. The value of our biomarkers to
identify patients most likely to benefit from bemcentinib is tremendous. Based
on our clinical data, more than 50% of AML/MDS patients are AXL positive, of
which 43% reported complete response within the first few weeks of starting
bemcentinib monotherapy treatment. Bemcentinib is very well tolerated by
patients as a single agent and in combination with other drugs, which is an
important feature supporting bemcentinib’s broad utility. We are making
excellent progress recruiting the chemotherapy combination arms of this study
and look forward to reporting the data from these patients in the coming
months”.

About AML
AML is the most common form of acute leukaemia in adults where malignant AML
blasts interfere with the normal functioning of the bone marrow leading to a
multitude of complications like anaemia, infections and bleeding. AML is
diagnosed in over 20,000 patients in the US annually and is rapidly lethal if
left untreated. Successful treatment typically requires intensive therapy or
bone marrow transplantation, and relapse and resistance are common.
Consequently, there is an urgent need for effective novel therapies in
relapsed/refractory patients, particularly those that are ineligible for
intensive therapy or bone marrow transplant.

About the BGBC003 trial
The BGBC003 trial is a phase Ib/II multi-centre open label study of bemcentinib
as a single agent in patients with AML or high risk MDS or in a combination with
cytarabine and decitabine in AML patients. Up to 75 patients will be enrolled at
centres in the US, Norway, Germany and Italy. For more information please access
trial NCT02488408 at www.clinicaltrials.gov.

About the 60th ASH Annual Meeting in San Diego, California
The 60th American Society of Haematologist Annual Meeting and Exposition is the
most comprehensive haematology conference worldwide and attracts more than
25,000 haematology professionals from every subspecialty.

About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple
cancer indications. The Company is a world leader in understanding the essential
role of AXL kinase in mediating cancer spread, immune evasion and drug
resistance in multiple aggressive solid and haematological cancers.
BerGenBio’s lead product, bemcentinib, is a selective, potent and orally bio
-available small molecule AXL inhibitor in four Company sponsored Phase II
clinical trials in major cancer indications, with read-outs anticipated in the
second half of 2018.

AXL kinase is cell membrane receptor and an essential mediator of the biological
mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL
drives tumour survival, treatment resistance and spread, as well as suppressing
the body’s immune response to tumours. AXL expression has been established as a
negative prognostic factor in many cancers. AXL inhibitors, therefore, have
potential value at the centre of cancer combination therapy, addressing
significant unmet medical needs and multiple high-value market opportunities.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO).
www.bergenbio.com

-Ends-

Contacts

Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

Media Relations in Norway
Jan Petter Stiff, Crux Advisers
[email protected]
+47 995 13 891

International Media Relations
David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
[email protected]

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Tr

http://www.netfonds.no/quotes/release.php?id=20181203.OBI.20181203S2

[Realize_1]

2018_ASH_Loges-et-al.pdf

[Flottesen]

Lovende dette, effekten har økt litt.

Overraskende å høre at andre del av studien allerede er fullt rekruttert, her må jo pasientene ha stått i kø. De tyder vel på at klinikerne har troen på konseptet.

[Flottesen]

Gitt at pasientene i første halvdel(monoterapi) fikk CR innen få uker, så bør vi vel kunne få spennende data om andre halvdel av studien(kombo med chemo) relativt tidlig i 2019?

[larsmkn]

Ja, dette var faktisk litt bedre enn det jeg trodde. Responsraten er en ting, men at mDoR er for lav sAXL er høyere en mDoR oppgitt i abstract var veldig fint å se. Det er kanskje lov å håpe på gode tall fra komboen eller?

Edit: men jeg syns det er litt rart at vi ikke har sett noe data fra dette studiet som nå plutselig er ferdig enrolled?

Don’t know what to make of that.

[Flottesen]

Det kan bli en bra desembermåned, det kommer til å hagle inn med børsmeldinger. Det er oppstart i flere investigator-sponsored studier pluss antistoff-studien.

Jeg tolker det som et godt tegn at studiene rekrutterer raskt, dette er jo i kontrast til de fleste andre norske selskapene. Selskapet har vel ikke vært veldig tydelig på studieoppsettet i AML/MDS, at det er todelt med en mono og en kombo -del.

[Flottesen]

28 november fikk Astellas godkjenning for gilteritinib i R/R AML, samme indikasjon som BGBIO nå viste resultater for. FDA hadde gitt fast track og priority review.
https://www.astellas.com/en/news/14406

Gilteritinib hemmer 2 mutasjoner som er drivere for AML, 7% av pasientene har disse driverne.
Det finnes en biomarkør som kan identifisere disse pasientene, på samme måte som BGBIO utvikler biomarkører for AXL.

Effekten?
Gilteritinib: 21% CR

Bemcentinib: 43% CR i følge data som ble presentert i natt.
Og pasientpopulasjonen ser ut til å være ca. 50% av AML pasientene.

Det må jo kunne sies å være lovende.

[TekBot]

12/12-2018 07:00:15: (BGBIO) BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB’s 9th Annual Nordic Healthcare Conference

· Bemcentinib proof of concept clinical data as monotherapy and in combination
confirms focus on lung cancer & leukaemia
· AXL biomarker correlation supports bemcentinib’s proposed MoA, potential for
…

Vis børsmeldingen

Companion Diagnostic
· Significant milestones expected over next 12 months
Bergen, Norway, 12 Dec 2018 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company focused on developing a pipeline of first-in-class AXL
kinase inhibitors to treat multiple cancer indications, announces that the
Company will be presenting key results from its Phase II clinical programme with
selective AXL inhibitor bemcentinib at the DNB’s 9th Annual Nordic Healthcare
Conference in Oslo, Norway, today at 10:15-10:40 CET.

The slides are available for download at the Company’s website:
www.bergenbio.com/investors/presentations/

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We have made
significant progress during 2018 establishing clinical proof of concept for the
remarkable utility of bemcentinib in cancers with high unmet clinical need and
large market potential. We have shown that our once-a-day, oral selective AXL
inhibitor is well tolerated as a monotherapy and in combination with immune-,
targeted and chemotherapies. What is more, consistently we have seen that
efficacy scales with AXL biomarker expression leading to superior response rates
in AXL biomarker positive relapsed/refractory AML and MDS as a monotherapy as
well as non-small cell lung cancer where we are combining with the immunotherapy
blockbuster Keytruda. We have met all our operational milestones this year and
are looking forward to starting a randomised phase II programme towards the end
of H1 2019 based on key results obtained this year.”

About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple
cancer indications. The Company is a world leader in understanding the essential
role of AXL kinase in mediating cancer spread, immune evasion and drug
resistance in multiple aggressive solid and haematological cancers.
BerGenBio’s lead product, bemcentinib, is a selective, potent and orally bio
-available small molecule AXL inhibitor in four Company sponsored Phase II
clinical trials in major cancer indications, with read-outs anticipated in the
second half of 2018.

AXL kinase is cell membrane receptor and an essential mediator of the biological
mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL
drives tumour survival, treatment resistance and spread, as well as suppressing
the body’s immune response to tumours. AXL expression has been established as a
negative prognostic factor in many cancers. AXL inhibitors, therefore, have
potential value at the centre of cancer combination therapy, addressing
significant unmet medical needs and multiple high-value market opportunities.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO).
www.bergenbio.com

-Ends-

Contacts

Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
[email protected]
+47 995 13 891

International Media Relations

David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
[email protected]
+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Tradi

http://www.netfonds.no/quotes/release.php?id=20181212.OBI.20181212S4

[Fornybar]

Hvordan få biotekinvestorene i Norge bli sinte på deg? Si at de ikke forstår selskapet.

Bergenbio-sjef: – Skuffet over markedets reaksjon - E24 Aksjelive

[larsmkn]

Jeg skjønner sjefen, men det er alltid selskapets feil om de ikke kan kommunisere på en forstålig måte. Det sagt så hjalp det tydeligvis i dag

[TekBot]

15/12-2018 11:11:00: (BGBIO) BerGenBio announces a change to its Board of Directors

Bergen, Norway, 15 December 2018 – BerGenBio ASA (OSE:BGBIO) announces that Dr.
Susan Foden has, for personal reasons, decided to stand down from her position
as a Non-executive Director and will leave the Board of Directors effective from
…

Vis børsmeldingen

1 January 2019.

BerGenBio’s Board Nominations Committee is currently working on recruiting a new
board member and it’s proposals will be made at the Company’s Annual General
Meeting on 13 March 2019.

Stein Holst Annexstad, Chairman of the Board of Directors, said: “On behalf of
the Board of Directors and the Company, I would like to thank Sue for her
excellent contribution and valued advice over the past 7 years. We wish her well
for the future.”

-Ends-

Contacts
Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading

http://www.netfonds.no/quotes/release.php?id=20181215.OBI.20181215S2

[Savepig]

Kan noen snart lære dem om et bedre standardsvar på dette ffs.

“Fra vårt ståsted hadde det jo selvfølgelig vært ønskelig om det var enda mer interesse rundt aksjen til selskapet som vi ikke mener har nådd sitt fulle potensiale og vi jobber selvsagt hardt med å spre informasjon til relevante investorer, men vi er overbevist om at hvis vi fokuserer mest på vårt vitenskaplige arbeid og fremskaffer overbevisende data så så vil også interessen komme som en naturlig konsekvens.”